US2020345760A1PendingUtilityA1
Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid
Est. expiryJan 29, 2036(~9.5 yrs left)· nominal 20-yr term from priority
A61K 47/36A61K 9/0048A61K 31/728A61P 27/02A61K 47/26A61K 31/737
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. The present invention also relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutical acceptable carrier.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A method for stabilizing an aqueous composition, wherein the method comprising adding sorbitol in an aqueous composition which comprises 20 to 60 mg/mL of chondroitin sulfate, 10 to 40 mg/mL of hyaluronic acid, and a pharmaceutically acceptable carrier, thereby stabilizing the aqueous composition at room temperature.
22 . A method of manufacturing an ophthalmic surgical aid, comprising including an aqueous composition in an ophthalmic surgical aid employed in an ophthalmic surgery for treating an ocular disease, wherein the aqueous composition comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutically acceptable carrier.
23 . The method of claim 22 , wherein the aqueous composition in the ophthalmic surgical aid is stored at room temperature.
24 . The method of claim 21 , wherein the sorbitol is D-sorbitol.
25 . The method of claim 21 , wherein the composition has a viscosity of 20,000 to 120,000 mPa·s at 25° C. and at a shear rate of 2 s −1 .
26 . The method of claim 21 , wherein the sorbitol concentration in the composition is 0.1 mg/mL or higher, 0.5 mg/mL or higher, 1 mg/mL or higher, 2 mg/mL or higher, 100 mg/mL or lower, 80 mg/mL or lower, 50 mg/mL or lower, 20 mg/mL or lower, 10 mg/mL or lower, 0.5 to 100 mg/mL, 1 to 80 mg/mL, 2 to 40 mg/mL, 2.5 to 20 mg/mL, or 5 to 10 mg/mL.
27 . The method of claim 21 , wherein the sorbitol concentration in the composition is 1 to 80 mg/mL.Join the waitlist — get patent alerts
Track US2020345760A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.